Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OCS-05+SoC administration · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| OCS-05 +SoC (corticosteroid) IV administration | DRUG | OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days |
| Placebo + SoC (corticosteroid) IV administration | OTHER | Placebo + SoC (corticosteroid) IV administration for 5 consecutive days |
OCS-05 is an investigational small molecule being studied for the treatment of optic neuritis, a neurological condition involving inflammation of the optic nerve. It is currently in Phase 2 clinical development, with one completed trial evaluating its effects in patients with optic neuritis.
OCS-05 is being developed by Oculis Holding AG, a biopharmaceutical company. The company's stock is traded under the ticker symbol OCS. Oculis is conducting clinical research to evaluate the safety and efficacy of OCS-05 in patients with optic neuritis.
OCS-05 is in Phase 2 clinical development. A Phase 2 trial, identified as NCT04762017, has been completed. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of optic neuritis.
OCS-05 has been evaluated in one clinical trial, NCT04762017, titled "OCS-05 in Patients With Optic Neuritis." This Phase 2 study enrolled 36 participants and has been completed. The trial was uncontrolled, meaning it did not include a placebo or comparator group.
OCS-05 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for optic neuritis. The completed Phase 2 trial, NCT04762017, has finished, but the drug has not yet received regulatory approval and remains under investigation.